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Abstract 
Commentaries published in INNOVATIONS in Pharmacy over the past 2 years have made the case that, as a basis for formulary decision 
making, the construction of imaginary modeled worlds fails to meet the standards of normal science. As such, they should be rejected 
as a basis for decision-making. While their proponents argue that imaginary constructs are key sources of information for formulary 
decisions, the fact is that the claims made from those models are impossible to validate. Indeed, they were never intended to be 
validated. Claims for product performance should be presented in evidentiary terms. That is, they should be credible, evaluable and 
replicable. If the commitment to imaginary worlds in technology assessment is to be abandoned a key requirement is for platforms 
that allow claims to be assessed in real time and in a timeframe that is meaningful to decision makers. Recent developments in 
blockchain technology offer the prospects for platforms that meet criteria for claims assessment.  
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Introduction 
Over the past few years the present author has published a 
number of commentaries in INNOVATIONS in Pharmacy that 
have made the case that the commitment in health technology 
assessment to the construction of imaginary worlds to support 
claims for product cost-effectiveness and pricing runs counter 
to the standards of normal science 1. Rather than focusing on 
the need for an evidence based assessment of claims for 
pharmaceutical products and devices in target patient 
populations, formulary committees and other health system 
decision makers have been asked to rely upon information 
‘constructed’ from imaginary worlds. This approach to decision-
making and the consequent lack of attempts to replicate claims 
following product formulary approval look set to continue. A 
situation which is exacerbated by the role of pricing, not only 
the choice of a product price consistent with initial modeled 
claims for cost-effectiveness, but the subsequent near term 
abandonment of that price in favor, at least in the US, of a 
pricing strategy that looks to annual or semi-annual price 
increases to generate target revenue flows. Needless-to-say, 
justifications for the continued increase in product prices, 
which all too often exceed not only consumer price indices but 
also medical cost indices, are either absent or lack credibility.  
 
The purpose of this commentary is to consider why this 
commitment to the construction of imaginary worlds remains a 
core activity in health technology assessment. Obviously, if a  
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single payer health system mandates or sets guidelines for the 
construction of modeled imaginary worlds to support formulary 
decision making, a manufacturer would be foolish to object. 
The construction of a modeled imaginary world is far less 
taxing, in time and costs, compared to suggestions of a 
commitment to underwriting a short-term prospective 
observational study or pragmatic trial to evaluate or replicate 
claims generated for clinical outcomes and modeled cost-
effectiveness from pivotal Phase 3 trials.  After all, there is 
always the risk of non-substantiation of claims. A risk, if the 
evidence for non-replication of trial outcomes is accepted, that 
is far from negligible. For a modeled lifetime cost-per-quality 
adjusted life year (QALY) model the question of replication is, 
of course, a non-starter. The claims, by construct, are non-
evaluable. 
 
In the US, the absence of a single payer system and the lack of 
support from government agencies in the construction of 
imaginary modeled worlds has not deterred professional 
associations such as the Academy of Managed Care Pharmacy 
(AMCP) and the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) from recommending the 
construction of imaginary worlds, typically lifetime cost-per-
QALY models; a position that is supported by the Institute for 
Clinical and Economic Research (ICER) 2 3 4. The ICER is of 
particular interest with the attention given to its modeled 
recommendations for pricing by manufacturers 5 6 7. The 
paradox appears to be that while manufacturers may criticize a 
specific ICER model, typically when the pricing and discounting 
recommendations are against the manufacturer, rather than 
challenge the utility of constructing imaginary worlds in the first 
place, the response of the manufacturer is to propose 
alternative and, inevitably, more favorable imaginary worlds. It 
is this apparent paradox and its potential resolution that will be 
examined here.   
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Absent Hypothesis Testing 
If there was any doubt as to the commitment by health 
technology assessment agencies to rejecting hypothesis testing 
of product claims in favor of imaginary constructs, the latest 
version of the Canadian CADTH guidelines makes this 
abundantly clear: Economic evaluation are designed to inform 
decisions. As such they are distinct from conventional research 
activities, which are designed to test hypotheses 8 9. The focus 
of the CADTH guidelines is on the construction of a cost per 
QALY reference case assessment of the expected cost-
effectiveness tradeoff of two or more interventions. The 
reference case is not intended to generate evaluable claims. In 
the framework that is presented the reference case 
extrapolates from currently available information. The time 
horizon of the reference case ‘should be long enough to 
consider all relevant differences in the future costs and 
outcomes associated with the interventions being compared’. If 
the intervention is for a chronic disease then the lifetime of the 
modeled index population is the framework for the reference 
case. This could extend decades into the future. Expressing the 
decision problem in lifetime cost-per-QALY terms excludes by 
definition any attempts to generate evaluable claims for 
competing products (or even claims for the product itself). The 
decision problem is based, therefore, on an arbitrary construct 
describing the future unknown course of a disease, replete with 
assumptions regarding future costs, outcomes, quality of life, 
co-morbid conditions, compliance and mortality. 
 
Resource Misallocation and Unintended Health Outcomes 
Relying on imaginary worlds to drive formulary decisions has 
the potential for significant resource misallocation and  
unintended health outcomes that may be driven by 
unevaluable product claims. Unfortunately, it is no defense to 
argue that one-modeled imaginary world is more ‘realistic’ than 
another. Where the model extends for decades beyond the 
short term where modeled claims might be evaluated, 
providing feedback to formulary committees, we have no idea 
whether the modeled claims are right or even if they are wrong, 
and we will never know. In the absence of a commitment by a 
manufacturer to (i) produce evaluable claims and (ii) undertake 
to evaluate those claims through prospective observational 
studies or, in the medium to long term, agree to a registry, there 
is no basis for re-assessing a decision let alone evaluating the 
extent to which such a formulary decision has led to resource 
misallocation and adverse health outcomes in target patient 
populations. 
 
The inability or unwillingness of manufacturers to develop and 
stand behind evaluable claims is made more problematic by the 
fragmented nature of US health data. Certainly, there are 
databases such as those generated from administrative claims, 
but these typically lack appropriate tracking and outcomes 
measures for clinical events. There are no data which monitor 
or track patients for their successive visits to their provider over 
the course of treatment with inputs from both the patient and 
the treating physician. Indeed, physician practices show little 
interest in generating their own data to assess aggregate 
response to therapy in target populations over the course of 
treatment, even to the extent of being able to respond to 
simple requests for the numbers of patients introduced to 
specific products or devices. Moving beyond this to 
implementing validated patient reported outcomes 
instruments to track responses, such as the Patient Global 
Impression of Change (PGIC) which is often found in phase 3 
randomized trials, seem outside a practice’s terms of reference. 
 
Belief in Modeling 
One question that has been asked, but with no satisfactory 
resolution, is whether formulary committees in the US and 
those outside of the professional fraternity of imaginary world 
architects, take modeled claims seriously? Do they see these 
claims as ‘useful’ information (whatever that means) or as a 
black box marketing device to set the stage for formulary 
positioning and pricing decisions. It is difficult to believe that 
formulary committees, faced with competing black box models 
for a manufacturer’s products and comparators, are in a 
position even to evaluate the competing merits of the modeled 
assumptions let alone the lifetime modeling techniques that are 
applied. After all, compared to agencies such as NICE in the UK 
and the PBAC in Australia, formulary committees are unlikely to 
have the resources to ask for an independent assessment of 
competing models. Even where these resources are available 
with a technical support group, the likelihood is that the group 
has accepted the informational rather than the evidentiary role 
of modeling claims. Whether they are even prepared to admit 
that lifetime cost-per-QALY claims were never intended to be 
anything other than constructed ‘information’ is an open 
question.   
 
Claims that a product, at the price determined by the 
manufacturer, is ‘cost-effective’ also lack credibility. Any price 
can be defended, in a constructed model, as cost-effective. This 
is seen in the ‘our model is more realistic than your model’ 
responses associated with ICER recommendations for price 
discounting under various willingness-to-pay scenarios. It is 
always possible to choose a price, tweak assumptions (or even 
provide an entirely different model structure) to support a price 
that falls below some willingness-to-pay threshold. It becomes 
a game. One imaginary construct is set against another. After 
all, as noted above, a price can be selected to ensure formulary 
acceptance (‘our product is cost-effective versus comparators’) 
followed in short order by a price increase that effectively junks 
the previous modeled claim. It is unusual, if not unheard of, for 
a formulary committee to ask for a reworking of a model after 
a future unilateral price increase by a manufacturer to re-
calibrate previous claims for comparative cost-effectiveness.  
 
Accepting Non-Evaluable Claims 
While it is possible to make the case that modeled ‘for 
information’ claims should be put to one side in favor of 
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credible evidence based claims, the fact is that constructing 
modeled claims continues to be the mainstay of academic 
groups and consultants in the US, whether these claims are 
couched in clinical or cost-effectiveness terms. An industry has 
developed around the AMCP guidelines, with continuing 
iterations of the guidelines still hewing to the lifetime cost-per-
QALY paradigm. Putting to one side the obvious attraction of 
mathematical modeling and building of lifetime frameworks as 
an academic ‘build your CV’ exercise and the willingness of 
journal editors to publish these models, a reasonable question 
is why does this persist? The ICER continues to have an impact 
and continues as a non-profit group to attract funds for 
constructing imaginary worlds. The ICER, in an important sense, 
sets the stage and establishes the parameters for non-
evaluable  ‘information’ which, given its recommendations, can 
be attacked or supported by manufacturers.  
 
The ICER process of engagement and its contracting with 
academic research centers, plus limited access granted to 
manufacturers to ‘assess’ the modeling framework, gives a seal 
of approval to the ‘information’ paradigm  10 11.  This is 
reinforced by the support for imaginary worlds given by AMCP, 
ISPOR and overseas single payer health system agencies. 
Everyone is on board. Manufacturer critiques of an adverse 
ICER recommendation are seen as a minor scuffle over 
assumptions; a rearranging of deckchairs, rather than an 
interest in generating and supporting evaluable claims.   
 
If there is no interest by manufacturers in moving to an 
evidence-based approach to formulary decision making, then it 
could be argued that if ICER did not exist it would have to be 
invented. ICER sets a seal of approval. It is part of a 
methodological guarantee that information only modeling is 
acceptable, regardless of the potential for adverse 
consequences and resource misallocation. More pertinent, 
perhaps, is that the focus on imaginary worlds deflects 
attention from the possibility of rigorous and ongoing evidence 
based reviews of product performance. If there is no possibility 
of evaluable claims then there is no basis for revisiting claims as 
part of disease area and therapeutic class reviews. Unless 
formulary committees are prepared to require manufacturers 
to submit evaluable product claims and underwrite protocols to 
assess those claims, as proposed in the Minnesota guidelines 
for formulary submissions decisions are made in what is 
virtually an evidence vacuum 12 13. At best, formulary 
committees are forced back on attempting to establish the 
external validity of typically short-term pivotal randomized trial 
claims. Attempts to undertake observational studies, establish 
registries or longer term randomized trials fall at the first 
hurdle: the absence of funding. The net result is that there is no 
feedback from physician practices on the effectiveness and 
comparative performance of the majority of pharmaceutical 
products and devices.  
 
Putting evidence based evaluations of health technologies to 
one side in favor of the construction of lifetime cost-per-QALY 
worlds has put health technology assessment outside of the 
mainstream of normal science. The imaginary worlds paradigm 
is, for all practical purposes, a dead end. Certainly, technology 
assessment agencies can continue to mandate imaginary 
constructs for ‘information’ purposes. Whether this adds to our 
ability to assess the value new technologies bring to the process 
of care is doubtful.   
 
A Platform for Evidence 
If a major reason for continuing to accept the modeled or 
constructed information paradigm is the absence of readily 
accessible and low cost platforms for claims assessment, then 
the question is whether or not it is possible to establish such a 
platform (or platforms by disease area) for health care systems?  
What would be the incentives for such a platform? Would it be 
possible to bring together the various disparate data elements 
that characterize the US health care system? Can 
interoperability be guaranteed? Can the security of data be 
guaranteed? Who would ‘own’ the platform? What access 
protocols would be required? Who would manage the 
platform? 
 
The first step towards establishing a platform would be to agree 
on the ownership of the platform data. Putting to one side the 
software appropriate to establishing a platform, it is worth 
noting that the Centers for Medicare and Medicaid Services 
(CMS) has formulated a proposed rule requiring healthcare 
organizations to provide patients with their health information 
in a universal electronic format 14. The CMS vision, building on 
the MyHealthEData initiative, is to put patients in control of 
their own health data so they can decide how it is used. If it 
proves possible to assign property rights to patients, this is the 
necessary first step. Unfortunately, we can be assured there will 
be well financed objections from current health data vendors 
to any arrangement that abrogates their perceived property 
rights and their revenue streams. Having to secure patient 
permission, for example, from literally tens of millions of 
patients in the case of administrative claims data would be is a 
major undertaking.  
 
According to CMS, establishing a platform that captures every 
encounter (including legacy encounters) within the health care 
system may reduce substantially practice administrative costs. 
At the same time the CMS objective is to drive innovation to 
create new ‘tools and solutions’ to support research and 
evidence-based guideline development. The goal is to connect 
‘seamlessly’ all records to the patient’s EMR. Whether this is 
practical is an open question given the plethora of EMR 
systems, their potential claims to property rights, and the 
additional need as patients move from one provider to another 
to transfer all records from one EMR system to another. 
Consideration does not appear to have been given to a platform 
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outside of EMRs which the patient subscribes to for their 
lifetime or which can be transferred to another platform. 
 
Blockchains as Platforms 
Increasing attention is being given to the role of blockchain 
software as platforms for the encrypted, safe storage of 
personal health records. A patient would subscribe to a 
blockchain and request all health records be copied. This data 
transfer would occur in real time (with legacy records captured 
on initial subscription) with all successive health system 
encounters, including data from devices. Ownership of the 
blockchain data would overcome issues of interoperability of 
records and facilitate portability of a complete medial history.  
 
Expecting patients to subscribe as individuals to a health 
blockchain is probably wishful thinking. They would have 
neither the time nor the skills and resources to organize record 
transfers, nor the skills to establish smart contracts for record 
access by third parties. The more likely scenario is the role of 
physician practice groups, specialty physician practices and 
health systems to encourage the adoption of blockchains by 
their patient population.  It is this scenario that sets the stage 
for an evidence platform with property rights assigned to the 
patient. As a first step the patient medical record held by the 
individual practice would be copied to the blockchain. 
Supplementary data from referrals and other encounters such 
as hospitalizations and urgent care and emergency room visits 
could be added as these recognize property rights and links are 
established to the platform for data retrieval.  
 
Even so, managing recruitment to the blockchain and the 
copying of health records are critical to establishing a viable 
platform. Management is most likely to be through the 
blockchain vendor. This would involve an agency contract with 
physician practices and health systems, with the vendor as 
gatekeeper to the blockchain to ensure property rights are 
recognized. Patients would be kept appraised of options to 
monetize to give access to their data by third parties. The 
blockchain management would provide the necessary indexing 
and search functions for data interrogation to identify target 
patient groups for third party access. 
 
While the potential for monetizing health data has been seen 
as a major incentive to blockchain adoption, blockchains are 
also a potentially critical tool for enhancing the process of care. 
Capturing data in real time can allow interactions between 
physician and patients to assess response to therapy as well as 
providing the framework for assessing evaluable product and 
device claims. The existence of blockchain platforms would 
allow formulary committees to put to one side decisions based 
on constructed ‘information’ in favor of real time claims 
assessment capturing feedback from patients and physicians.  
 
A blockchain platform is not a disease registry. While this may 
be obvious it is worthwhile noting the synergies between 
disease registries and a blockchain platform. If property rights 
are recognized then the contribution a patient or the provider 
on the patient’s behalf makes to the registry should be captured 
by the blockchain. At the same time, recognizing the inherent 
property rights of the patient opens up the opportunity for the 
patient to monetize their registry membership rather than 
assigning their rights to the registry owner. Blockchains also 
allow for the recruitment to registries through their ability to 
identify target patient populations and assign registry 
membership criteria (e.g., risk stratification of patients). Once a 
platform is established, registries can be accommodated within 
the blockchain. This offers a potentially significant source of 
revenue to the blockchain vendor as manager as well as 
monetization opportunities for the patient. The added 
advantage, of course, is that embedding a registry within a 
blockchain gives access to the patient’s complete medical 
record, supplementing and providing added value to the 
registry data.  
 
Conclusions 
From the perspective of health technology assessment, the 
ability to abandon constructed claims for comparative 
performance based on lifetime cost-per-QALY models is a 
necessary next step. The adoption of blockchain software offers 
this possibility. A blockchain platform has the potential to 
support and provide feedback in real time for claims made by 
manufacturers. Protocols can be developed, target patient 
groups identified, smart contracts exchanged and incentives 
provided for patient and, if required, physician engagement. 
This is not going to be easy. There are many vested interests 
focused on maintaining the present system, ranging from the 
health technology assessment community to data vendors. 
Property rights may be challenged. Healthcare systems may 
claim they have insufficient resources and incentives. 
Manufacturers may be reluctant to support the credible claims 
evaluation. Incentives may be misaligned with uptake of the 
platform. These are all obstacles to consider and to set against 
a significant unmet medical need in applying the standards of 
normal science to formulary decisions.   
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